what this node claims
AlphaFold metrics / GHRHR
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
52%
low debt pressure
21%
76%structureusable
pLDDT 75.82
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 75.82
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 75.82
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
423 residues / min 30.53 / max 97.0 / source alphafold db
Very high
26.5%
112 residues / >=90
Confident
41.4%
175 residues / 70-89
Low
20.1%
85 residues / 50-69
Very low
12.1%
51 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 423 of 423 residues.
- residues 393-423 / mean 40.48
- residues 1-29 / mean 39.9
- residues 313-328 / mean 60.18
- residues 343-358 / mean 63.55
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.